Previous 10 | Next 10 |
November was a very strong month for the market, being up 3.40%. My portfolio underperformed the market by more than 1.50% due to bad Cisco Systems (CSCO) earnings and negative stock fluctuations for the cyclical company AMG ( AMVMF ). On the positive side, I cashed in half of my Galapagos ( G...
We have a fantastic pipeline with a number of potentially blockbuster molecules moving towards the market. ~ Mr Onno van de Stolpe, CEO of Galapagos I recently interviewed Onno van de Stolpe, CEO of Galapagos ( GLPG ). Mr. van de Stolpe founded Galapagos in 1999 and has been its CE...
Does the company have products or services with sufficient market potential to make possible a sizable increase in sales for at least several years? - Philip Fisher If you've been following my work, you'd noticed that fundamental analysis is my cup of tea. In other words, forecasting cli...
Bausch Health Companies (NYSE: BHC ) initiated with Neutral rating and C$40 (7% upside) price target at Goldman Sachs. Shares up 2% premarket. More news on: Bausch Health Companies Inc., Centogene N.V., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ....
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Another Source Of Alpha Since June 2017, I've run a Marketplace service which has an " investing with a helmet on " approach: I present concentrated portfolios where each security is hedged. To construct these ...
The lead drug candidate of Galapagos ( GLPG ) is filgotinib, which many analysts consider a potential blockbuster drug. However, in 2015, Galapagos sold the rights to filgotinib to Gilead ( GILD ) for a 15% (25% now in 2019), $425mn stake in Galapagos, $1.35bn in milestone payments and between...
Gilead Sciences (NASDAQ: GILD) failed to impress investors with its latest earnings report released on Oct. 24. Not only did the company's revenues remain pretty much flat compared to the year-ago period, but the pharma giant's GAAP net income of more than $2 billion in Q3 2018 turn...
-- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease-Modifying Antirheumatic Drug(s) (csDMARDs) -- -- Data Demonstrate Effic...
Dear fellow investors, I started writing for Seeking Alpha in August and I really enjoyed it. I believe the time has come to give my "followers" something extra by fully disclosing my portfolio performance monthly. As such, I started a totally new Seeking Alpha portfolio with an initial invest...
Shares of Galapagos (NASDAQ: GLPG) gained over 20% last month, according to data provided by S&P Global Market Intelligence . The Belgian pharmaceutical company reported third-quarter 2019 operating results that reminded investors of its long-term potential. The business generated reven...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...